.png){kind=icon}
返回
M
Mariana Castanheira
JMI Laboratories
81H指数
646论文数
2.5W被引数
收录论文 243
发表时间
.png){kind=icon}
Characterization of isolates from two phase 3 uncomplicated urinary tract infection trials (EAGLE-2 and EAGLE-3) that show an apparent ≥4-fold increase in gepotidacin MIC between baseline and post-baseline visits来自两项III期非复杂性尿路感染试验（EAGLE-2和EAGLE-3）的分离株特征，这些分离株在基线与基线后访视期间表现出≥4倍的增加的gepotidacin MIC.png)
OAAI
.png){kind=icon}
OAAI.png){kind=icon}
分享.png){kind=icon}
收藏Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance programcefiderocol对来自美国和欧洲 (2020-2023) 具有难以治疗的耐药表型的铜绿假单胞菌的活性，包括对最近开发的 β-内酰胺/β-内酰胺酶抑制剂组合不敏感的那些: SENTRY抗菌药物监测计划的结果
PREAI
分享收藏Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023)Sader, H.S.; Kimbrough, J.H.; Winkler, M.L.; Castanheira, M.; Mendes, R.E. 阿兹treonam/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床使用批准前5年（2019–2023）的监测总结。J. Antimicrob. Chemother. 2025, 80, 2070–2079. [Google Scholar] [CrossRef]OAAI
OAAI分享收藏In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals头孢地洛尔对肠杆菌，铜绿假单胞菌和不动杆菌属的体外活性评估，包括对 β-内酰胺不敏感的分子特征分离株，2020年美国和欧洲医院的2021年收集
OAAI
OAAI分享收藏